Expression of lysosomal protective protein/cathepsin A in a stably transformed human neuroblastoma cell line during bi-directional differentiation into neuronal and Schwannian cells

Neurochemistry International

Volumn 44, Issue 6, 2004, Pages 447-457

  Itoh, Kohji ^a   Satoh, Yurie ^a   Kadota, Yoshito ^a   Oheda, Yukako ^a   Kuwahara, Jun ^a   Shimmoto, Michie ^b   Sakuraba, Hitoshi ^b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Enzyme replacement therapy; Galactosialidosis; Mannose 6 phosphate receptor; Neuroblastoma cell differentiation; Protective protein cathepsin A

Indexed keywords

BETA GALACTOSIDASE; BROXURIDINE; BUCLADESINE; CARBOXYPEPTIDASE C; CELL PROTEIN; COMPLEMENTARY DNA; ENZYME PRECURSOR; LYSOSOMAL PROTECTIVE PROTEIN; RECOMBINANT PROTEIN; SIALIDASE; SOMATOMEDIN B RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; BRAIN NERVE CELL; CELL GRANULE; CELL TRANSFORMATION; CHO CELL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FIBROBLAST; GALACTOSIALIDOSIS; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LYSOSOME; NERVE CELL CULTURE; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN SECRETION; SCHWANN CELL;

EID: 0347479315     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2003.07.001     Document Type: Article

References (40)

1. d'Azzo A., Hoogeveen A.T., Reuser A.J.J., Robinson D., Galjart H. Molecular defect in combined β-galactosidase and neuraminidase deficiency in man. Proc. Natl. Acad. Sci. U.S.A. 79:1982;4535-4539.
2. d'Azzo, A., Andria, G., Strisciuglio, P., Galjaard, H., 2000. Galactosialidosis. In: Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D. (Eds.), The Metabolic and Molecular Bases of Inherited Disease, eighth ed. McGraw-Hill, New York, pp. 3811-3826.
3. Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Mankin H.J., Murray G.J., Parker R.I., Argoff C.E. Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324:1991;1464-1470.
4. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldak S., Caplan L., Linthorst G.E., Desnick R.J. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N. Engl. J. Med. 325:2001;9-16.
5. Galjart H.J., Gillemans N., Harris A., van der Horst G.T., Verheijen F.W., Galjaard H., d'Azzo A. Expression of cDNA encoding the human 'protective protein' associated with lysosomal β-galactosidase and neuraminidase: homology to yeast proteases. Cell. 54:1988;755-764.
6. Hahn C., Martin M., Zhou X., Mann L., d'Azzo A. Correction of murine galactosialidosis by bone marrow-derived macrophage overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promotor. Proc. Natl. Acad. Sci. U.S.A. 95:1998;14880-14885.
7. Hanna W.L., Turbov J.M., Jackman H.L., Tan F., Froelich C.J. Dominant chymotrypsin-like esterase activity in human lymphocyte granules is mediated by the serine carboxypeptidase called cathepsin A-like protective protein. J. Immunol. 153:1994;4663-4672.
8. Hasegawa T., Yamaguchi K., Wada T., Takeda A., Itoyama Y., Miyagi T. Molecular cloning of mouse ganglioside sialidase and its increased expression in Neuro2a cell differentiation. J. Biol. Chem. 275:2000;8007-8015.
9. Itoh K., Takiyama N., Nagao Y., Oshima A., Sakuraba H., Potier M., Suzuki Y. Acid carboxypeptidase deficiency in galactosialidosis. Jpn. J. Hum. Genet. 36:1991;169-175.
10. Itoh K., Takiyama N., Kase R., Kondoh K., Sano A., Oshima A., Sakuraba H., Suzuki Y. Purification and characterization of human lysosomal protective protein expressed in stably transformed Chinese hamster ovary cells. J. Biol. Chem. 268:1993;1180-1186.
11. Itoh K., Kase R., Shimmoto M., Satake A., Sakuraba H., Suzuki Y. Protective protein as an endogenous endothelin degradation enzyme in human tissues. J. Biol. Chem. 270:1995;515-518.
12. Itoh K., Naganawa Y., Kamei S., Shimmoto M., Sakuraba H. Stabilizing effect of lysosomal β-galactosidase on the catalytic activity of protective protein/cathepsin A secreted by human platelets. Biochem. Biophys. Res. Commun. 253:1998;228-234.
13. Itoh K., Oyanagi K., Takahashi H., Sato T., Hashizume Y., Shimmoto M., Sakuraba H. Endothelin-1 in the brain of patients with galactosialidosis: its abnormal increase and distribution pattern. Ann. Neurol. 47:2000;122-126.
14. Jackman H.L., Tan F.L., Tamei H., Beurling-Harbury C. A peptidase in human platelets that deamidates tachykinins. Probable identity with the lysosomal 'protective protein'. J. Biol. Chem. 265:1990;11265-11272.
15. Jackman H.L., Morris P.W., Deddish P.A., Skidgel R.A., Erdos E.G. Inactivation of endothelin-1 by deamidase (lysosomal protective protein). J. Biol. Chem. 267:1992;2872-2875.
16. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
17. Leimig T., Mann L., Martin M.P., Bonten E., Persons D., Knowles J., Allay J.A., Cunningham J., Nienhuis A.W., Smeyne R., d'Azzo A. Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells. Blood. 99:2002;3169-3178.
18. Lukong K.E., Seyrantepe V., Landry K., Trudel S., Ahmad A., Gahl W.A., Lefrancois S., Morales C.R., Pshezhetsky A.V. Intracellular distribution of lysosomal sialidase is controlled by the internalization signal in its cytoplasmic tail. J. Biol. Chem. 49:2001;46172-46181.
19. Miyagi T., Wada T., Iwamatsu A., Hata K., Yoshikawa Y., Tokuyama S., Sawada M. Molecular cloning and characterization of a plasma membrane-associated sialidase specific for gangliosides. J. Biol. Chem. 274:1999;5004-5011.
20. Naganawa Y., Itoh K., Shimmoto M., Kamei S., Takuguti K., Doi H., Sakuraba H. Stable expression of protective protein/cathepsin A-green fluorescent protein fusion genes in a fibroblastic cell line from a galactosialidosis patient. Biochemical J. 340:1999;467-474.
21. Proshin S., Yamaguchi K., Wada T., Miyagi T. Modulation of neuritogenesis by ganglioside-specific sialidase (Neu-3) in human neuroblastoma NB-1 cells. Neurochem. Res. 27:2002;841-846.
22. Pshezhetsky A.V., Potier M. Association of N-acetylgalactosamine-6- sulfate sulfatase with the multienzymic lysosomal complex of β-galactosidase, cathepsin A and neuraminidase: possible implication for intralysosomal catabolism of keratan sulfate. J. Biol. Chem. 271:1996;28359-28365.
23. Pshezhetsky A.V., Elsliger M.-A., Vinogradova M.V., Potier M. Human lysosomal β-galactosidase-cathepsin A complex: definition of the β-galactosidase-binding interface on cathepsin A. Biochemistry. 34:1995;2431-2440.
24. von Reitzenstein C., Schuhmann V., Cantz M. Differential functional relevance of a plasma membrane ganglioside sialidase in cholinergic and adrenergic neuroblastoma cell lines. Eur. J. Biochem. 268:2001;326-333.
25. Reminigton S.J., Breddam K. Carboxypeptidase C and D. Methods Enzymol. 244:1994;231-248.
26. Rudenko G., Bonten E., d'Azzo A., Hol W.G.J. Three-dimensional structure of the human 'protective protein': structure of the precursor form suggests a complex activation mechanism. Structure. 3:1995;1249-1259.
27. Saito Y., Saido T.-C., Sano K., Kawashima S. The calpain-calpastatin system is regulated differently during human neuroblastoma cell differentiation to Schwannian and neuronal cells. FEBS Lett. 353:1994;327-331.
28. Sakuraba H., Aoyagi T., Suzuki Y. Galactosialidosis (β- galactosidase-neuraminidase deficiency): a possible role of serine-thiol proteases in the degradation of β-galactosidase molecules. Clin. Chim. Acta. 125:1982;275-283.
29. Sands M.S., Volger C.A., Ohlemiller K.K., Roberts M.S., Grubb J.H., Levy B., Sly W.S. Biodistribution, kinetics, and efficacy of high phosphorylated and non-phosphorylated β-glucuronidase in the murine model of mucopolysaccharidosis VII. J. Biol. Chem. 276:2001;43160-43165.
30. Satake A., Itoh K., Shimmoto M., Saido T.C., Sakuraba H., Suzuki Y. Distribution of lysosomal protective protein in human tissues. Biochem. Biophys. Res. Commun. 205:1994;38-45.
31. Schiffman R., Kopp J.B., Austin H.A., Sabnis S., Moore D.F., Weibel T., Balow J.B., Brady R.O. Enzyme replacement therapy in Fabry disease - a randomized controlled trial. JAMA. 285:2001;2743-2749.
32. Sekiguchi M., Oota T., Sakakibara K., Inui N., Fujii G. Establishment and characterization of a human neuroblastoma cell line in tissue culture. Jpn. J. Exp. Med. 49:1979;67-83.
33. Shimmoto M., Fukuhara Y., Itoh K., Oshima A., Sakuraba H., Suzuki Y. Protective protein gene mutations in galactosialidosis. J. Clin. Invest. 91:1993;2393-2398.
34. van der Spoel A., Bonten E., d'Azzo A. Transport of human lysosomal neuraminidase to mature lysosomes requires protective protein/cathepsin A. EMBO J. 17:1998;1588-1597.
35. Sugimoto T., Kato K., Sawada T., Horii Y., Kemshead J.T., Hino T., Morioka H., Hosoi H. Schwannian cell differentiation of human neuroblastoma cell lines in vitro induced by bromodeoxyuridine. Cancer Res. 48:1988;2531-2537.
36. Tsunamoto K., Todo S., Imashuku S., Kato K. Induction of S-100 protein by 5-bromo-2′-deoxyuridine in human neuroblastoma cell lines. Cancer Res. 48:1988;170-174.
37. Tsuneishi S., Sano K., Nakamura H. Serum depletion increases the neurofilament protein mRNA levels in a neuroblastoma cell line, GOTO. Mol. Brain Res. 17:1993;119-128.
38. Verheijen F.W., Palmeri S., Hoogeveen A.T., Galjaard H. Human placental neuraminidase: activation, stabilization and association with β-galactosidase and its 'protective' protein. Eur. J. Biochem. 149:1985;315-321.
39. Volger C., Levy B., Galvin N.J., Thorpe C., Sands M.S., Barker J.E., Baty J., Birkenmeier E.H., Sly W.S. Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. Pediatric Res. 45:1999;838-844.
40. Zhou X.Y., Morreau H., Rottier R., Davis D., Bonten E.J., Gillemans N., Wenger D., Grosveld F.G., Doherty P., Suzuki K., Grosveld G.C., d'Azzo A. Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with overexpressing erythroid precursor cells. Gene Dev. 9:1995;2623-2634.